There’s a balance required to manage both the symptoms of myelofibrosis through treatment and the side effects caused by the drugs, explained Firas El Chaer, MD, of the University of Virginia School of Medicine.
The significant symptom burden of myelofibrosis requires treatment to control symptoms, but the Janus kinase (JAK) inhibitors being used today can cause significant side effects that are hard to manage through dose adjustment or reduction and may require patients to switch to a different class of drug to maintain disease control of myeloproliferative neoplasms (MPNs), explained Firas El Chaer, MD, associate professor of medicine, University of Virginia School of Medicine.
This transcript has been lightly edited for clarity.
Transcript
What impact do the symptoms of MPNs have on the quality of life of patients?
Unfortunately, untreated myelofibrosis can be associated with significant symptom burden, and without treatment, those symptoms don't usually improve on their own. We're very lucky that we have drugs right now that can control those symptoms. However, unfortunately, in a lot of instances, the disease can relapse with these symptoms, progressing on further therapy, requiring additional therapeutic agents in the future. Those symptoms can be quite debilitating, so controlling them is very important.
What are common adverse events from MPN treatment and how can they best be managed?
Many of the JAK inhibitors that we use nowadays can have significant side effects, such as severe thrombocytopenia, severe anemia, and sometimes they can have GI [gastrointestinal] side effects. One drug, momelotinib, for instance, can have neuropathy side effects. And in some instances, these side effects can be very hard to manage. They might require dose reduction and drugs, which ultimately can lead to a subtherapeutic effect of those drugs. So, knowing how to dose adjust these medications to prevent further side effects is very important.
However, unfortunately, in a lot of instances, we cannot really dose reduce or dose adjust while keeping control of the disease, forcing us to switch to a different drug or different class of drugs to be able to treat those patients.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays
April 17th 2025Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Read More
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More